By Ben Fidler | September 25, 2026
The biopharmaceutical landscape shifted significantly this week as major players navigated a complex web of high-stakes litigation, strategic partnerships, and pivotal regulatory milestones. From Novo Nordisk’s aggressive pursuit of long-acting injection technology to Eli Lilly’s mixed bag of courtroom outcomes and blockbuster drug approvals, the industry is demonstrating a clear trend: the race to simplify treatment regimens for chronic conditions is accelerating, while the legal battles over intellectual property and partnership integrity remain as contentious as ever.
1. Main Facts: A Week of Strategic Realignment
The week’s news cycle was dominated by four primary developments that underscore the current priorities of the world’s leading pharmaceutical firms:
- Novo Nordisk’s Long-Acting Ambitions: In a move to solidify its dominance in the cardiometabolic space, Novo Nordisk has entered into a massive $1.32 billion licensing and collaboration agreement with the Swedish biotech firm Nanexa. The deal focuses on leveraging Nanexa’s proprietary "PharmaShell" drug delivery platform to develop injectable therapies for obesity and Type 2 diabetes that require administration only once a month or once a quarter.
- Acadia’s Gamble on Remlifanserin: Despite a clinical setback where their Alzheimer’s disease psychosis candidate, remlifanserin, narrowly missed the primary endpoint of statistical significance in a Phase 2 trial, Acadia Pharmaceuticals is pressing forward. The company has opted to continue its Phase 3 clinical program, citing the drug’s safety profile and the potential for success in larger, better-powered studies.
- The Nektar vs. Lilly Legal Saga: A California federal jury delivered a verdict in the high-profile lawsuit brought by Nektar Therapeutics against Eli Lilly. While Nektar successfully proved that Lilly undermined their collaborative autoimmune project, the $90 million damages award fell significantly short of the near $1 billion the plaintiff had originally sought.
- Regulatory Wins for Lilly and Merck: The FDA has expanded the treatment landscape for both Type 2 diabetes and renal cell carcinoma. Eli Lilly received a major approval for "Onswik," a once-weekly insulin, while Merck & Co. secured an expanded label for its kidney cancer therapy, Welireg, for patients whose disease has progressed after treatment with Keytruda.
2. Chronology of Events
The intensity of these developments reflects a high-pressure environment where every clinical readout and court date carries multi-billion-dollar implications.
- August 2023: Nektar Therapeutics initiates a lawsuit against Eli Lilly, alleging breach of contract and bad faith in their collaborative development of an autoimmune treatment.
- March 2026: The FDA grants approval to Novo Nordisk’s Awiqli, the first once-weekly basal insulin for adults with Type 2 diabetes, setting the stage for a direct market rivalry with upcoming competitors.
- Early September 2026: Acadia Pharmaceuticals announces topline results for its Phase 2 study of remlifanserin. The "near miss" of statistical significance triggers a sharp sell-off in company shares.
- September 24, 2026: A California federal jury reaches a verdict in the Nektar vs. Lilly trial, awarding $90 million to Nektar.
- September 25, 2026: Novo Nordisk officially confirms its global licensing deal with Nanexa. Concurrently, the FDA clears Lilly’s once-weekly insulin, Onswik, and approves an expanded indication for Merck’s Welireg.
3. Supporting Data and Market Dynamics
Novo Nordisk and the Nanexa Partnership
The $1.32 billion agreement (1.165 billion euros) is a testament to the high premium placed on patient compliance. By utilizing PharmaShell—a technology designed to provide controlled, sustained release of active pharmaceutical ingredients—Novo aims to reduce the "injection burden" for patients suffering from chronic metabolic disorders. The deal includes upfront payments and milestone-based payouts totaling 615 million euros. This is not Nanexa’s first foray into the big leagues; the company previously secured a similar deal with Moderna, proving that their shell-based delivery system is becoming a gold standard for companies looking to extend the half-life of their biologics.
The Efficacy of Once-Weekly Insulin
The approval of Lilly’s Onswik brings a formidable challenger to the market. In clinical trials, Onswik demonstrated non-inferiority compared to traditional daily insulin shots. The primary clinical value proposition here is convenience—a critical factor in the diabetes market where adherence is notoriously low. With Novo’s Awiqli already established in the market, the diabetes space is now entering an era of "convenience-based competition," where the dosing schedule is as important as the metabolic efficacy itself.
Welireg’s Continued Expansion
Merck’s Welireg is quickly becoming a cornerstone of its oncology portfolio. Since its 2019 acquisition from Peloton Therapeutics, the drug has performed remarkably well. With $470 million in sales during the first half of 2026 alone, the addition of a post-Keytruda indication for renal cell carcinoma significantly expands the addressable patient population. This move is part of Merck’s broader strategy to maintain its oncology leadership as the "Keytruda era" eventually faces patent cliffs.
4. Official Responses and Industry Sentiment
The atmosphere surrounding these announcements is one of cautious optimism tempered by corporate pragmatism.
Acadia Pharmaceuticals’ Position:
Despite the disappointment of the Phase 2 data, Acadia’s management remains steadfast. Their decision to proceed with two Phase 3 trials is based on the "favorable safety profile" of remlifanserin. The company argues that the Phase 2 study was not designed to show broad efficacy across a heterogenous population, and that the refined parameters of the upcoming Phase 3 trials will highlight the drug’s potential.
Analyst Perspectives:
Market analysts have provided a sobering reality check. Stifel analyst Paul Matteis noted that while the debate over remlifanserin’s future will continue, the Phase 2 trial was "well-powered," making the modest efficacy findings concerning. The double-digit drop in Acadia’s stock price reflects the market’s skepticism regarding the drug’s path to approval.
The Legal Verdict:
Nektar Therapeutics, in a regulatory filing, acknowledged the $90 million verdict as a partial victory, though it remains subject to post-trial proceedings. The disparity between the requested $1 billion and the awarded $90 million suggests that while the jury found merit in Nektar’s claims of bad faith, they were not convinced that the financial damages were as catastrophic as the company claimed.
5. Broader Implications for the Biopharma Sector
The Rise of "Convenience Engineering"
The Novo-Nanexa partnership and the FDA approval of Onswik highlight a broader shift in biopharma R&D. Innovation is no longer just about discovering new molecules; it is about "convenience engineering"—finding ways to make existing therapies easier to tolerate and manage. For patients, this means fewer disruptions to daily life. For pharmaceutical companies, this means extending the lifecycle of their products through superior delivery mechanisms that create a competitive moat against biosimilars and generics.
The Risk of Litigation in Collaborative Models
The Nektar vs. Lilly case serves as a cautionary tale for the industry. Strategic alliances are the lifeblood of modern drug development, but they are fraught with potential for conflict. When a large pharmaceutical company acquires a competing asset, it creates an inherent conflict of interest that can jeopardize smaller partners. This legal outcome will likely lead to more robust "anti-dilution" and "commitment-to-development" clauses in future partnership contracts.
The "Narrow Miss" Dilemma
Acadia’s situation highlights the difficulty of modern clinical trial design. In the rush to bring Alzheimer’s therapies to market, the pressure to show success in mid-stage trials is immense. However, when a trial "narrowly misses" statistical significance, companies face a difficult choice: abandon the asset and lose the R&D investment, or double down with a Phase 3 trial that carries significant financial risk. The industry will be watching Acadia closely, as their outcome could set a precedent for how companies handle "borderline" clinical data in the future.
Regulatory Pacing
The FDA’s swift actions regarding both Lilly and Merck underscore a regulatory environment that is increasingly favorable to drugs that address clear clinical needs, particularly in oncology and metabolic disease. The rapid approval of multiple once-weekly insulin options suggests that the FDA is prioritizing the modernization of chronic disease management, which should encourage other firms to prioritize long-acting, patient-centric delivery technologies.
As we move into the final quarter of 2026, these four stories serve as a microcosm of the industry at large: a sector that is balancing the immense potential of new drug delivery platforms with the logistical and legal realities of managing a global, multi-billion-dollar portfolio of assets. The winners in the coming year will be those who can successfully navigate both the clinic and the courtroom, ensuring that innovation reaches the patient with the least possible friction.
